Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

Roy Vergis, Catherine M Corbishley, Andrew R Norman, Jaclyn Bartlett, Sameer Jhavar, Michael Borre, Sara Heeboll, Alan Horwich, Robert Huddart, Vincent Khoo, Ros Eeles, Colin Cooper, Matthew Sydes, David Dearnaley, Chris Parker

Research output: Contribution to journalArticlepeer-review

222 Citations (Scopus)

Abstract

Expression of intrinsic markers of tumour hypoxia and angiogenesis are important predictors of radiotherapeutic, and possibly surgical, outcome in several cancers. Extent of tumour hypoxia in localised prostate cancer is comparable to that in other cancers, but few data exist on the association of extent of tumour hypoxia with treatment outcome. We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically.
Original languageEnglish
Pages (from-to)342-351
Number of pages10
JournalThe Lancet Oncology
Volume9
Issue number4
DOIs
Publication statusPublished - Apr 2008

Keywords

  • Aged
  • Aged 80 and over
  • Biopsy (Needle)
  • Cell Hypoxia
  • Cohort Studies
  • Humans
  • Hypoxia-Inducible Factor 1
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neovascularization (Pathologic)
  • Osteopontin
  • Probability
  • Prognosis
  • Proportional Hazards Models
  • Prostate-Specific Antigen
  • Prostatectomy
  • Prostatic Neoplasms
  • Radiotherapy, Conformal
  • Randomized Controlled Trials as Topic
  • Reference Values
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome
  • Tumor Markers (Biological)
  • Vascular Endothelial Growth Factor A

Cite this